Area of research
Pulmonary and Respiratory Medicine · Rheumatology
Research interest
Research interests include Vasculitis and related conditions, Systemic Sclerosis and Related Diseases, Otitis Media and Relapsing Polychondritis, and Systemic Lupus Erythematosus Research.
Association between anti-synthetase syndrome and malignancy: a systematic review and meta-analysis.
Cough as a clinical manifestation of giant cell arteritis.
18F-Fluorodeoxyglucose Positron Emission Tomography Imaging Assessment Within a Randomized Controlled Trial in Giant Cell Arteritis.
Spectrum and significance of 18F-FDG-PET/CT abnormalities in VEXAS syndrome.
A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis
Why, how and when to look for occult giant cell arteritis in patients with polymyalgia rheumatica.
External validation of the polymyalgia rheumatica impact scale: a prospective cohort study.
Large vessel vasculitis is a risk factor for relapse only in giant cell arteritis patients without polymyalgia rheumatica.
Highlights from the breakout session: imaging in disease assessment.
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update.
Prevalence, characteristics, and outcome of subclinical vasculitis in polymyalgia rheumatica: a retrospective cohort study.
Comparison of diagnostic spectrum between inflammation of unknown origin and fever of unknown origin: A systematic review and meta-analysis
Comparison of symptoms between diagnosis and relapse in giant cell arteritis: a retrospective cohort study.
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update
Diagnostic yield of combined cranial and large vessel PET/CT, ultrasound and MRI in giant cell arteritis: A systematic review and meta-analysis
Association Between Vascular <sup>18</sup>F-Fluorodeoxyglucose Uptake at Diagnosis and Change in Aortic Dimensions in Giant Cell Arteritis
Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group
Higher diagnostic yield of 18F-FDG PET in inflammation of unknown origin compared to fever of unknown origin
Association between diagnostic outcomes and symptom pattern in fever and inflammation of unknown origin
The 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis and Takayasu arteritis: comment on the articles by Ponte et al and Grayson et al.
OP0102 IDENTIFICATION OF NEW RISK LOCI AND PATHWAYS INVOLVED IN GCA PATHOGENESIS BY A GENOME-WIDE STUDY
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data
Epidemiology and predictors of relapse in giant cell arteritis: A systematic review and meta-analysis
Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies
Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5
Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome
Systemic autoinflammatory disease in adults
Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study